MXiPr

From PsychonautWiki
(Redirected from Methoxisopropamine)
Jump to navigation Jump to search
Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Songbird-egg.svg

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Summary sheet: MXiPr
MXiPr
Chemical Nomenclature
Common names MXiPR, MXiP
Substitutive name 3-MeO-2′-Oxo-PCiPr
Systematic name 2-(Isopropylamino)-2-(3-methoxyphenyl)cyclohexanone
Class Membership
Psychoactive class Dissociative
Chemical class Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 mg
Light 10 - 20 mg
Common 20 - 40 mg
Strong 40 - 60 mg
Heavy 60 mg +
Duration
Total 2 - 5 hours
Onset 20 - 60 minutes
After effects 4 - 48 hours



Insufflated
Dosage
Threshold 5 mg
Light 10 - 20 mg
Common 20 - 40 mg
Strong 40 - 60 mg
Heavy 60 mg +
Duration
Total 1.5 - 4 hours
Onset 2 - 5 minutes
After effects 2 - 12 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions

2-(Isopropylamino)-2-(3-methoxyphenyl)cyclohexanone (also known as 3-MeO-2′-Oxo-PCiPr and MXiPr) is a novel dissociative substance of the arylcyclohexylamine class. It is a structural analog of MXE. The mechanism is not known, but it is likely an NMDA receptor antagonist.

The circumstances surrounding MXiPr's origins are not known. It first appeared on the online research chemical market in late 2020[1] and was specifically marketed as a legal substitute for MXE or ketamine. The initial batch reportedly smelled like plastic and was suspected of containing impurities.

Subjective effects are comparable to ketamine and include sedation, motor control loss, pain relief, internal hallucinations, conceptual thinking, euphoria, and dissociation. Its subjective effects are described as similar to O-PCE or MXE, except more unpredictable and/or blissful in nature. It is thought to be slightly more potent than MXPr as well as a strong serotonin reuptake inhibitor like MXE.

Very little data exists about the pharmacological properties, metabolism, and toxicity of MXiPr, and it has a very brief history of human usage. Given the reports of impure batches, it is advised to purify this substance (please see this section and send it into a chemical testing service before use.

It is strongly advised to use harm reduction practices if using this substance.

History and culture

MXiPr first appeared for sale on the online research chemical market in late 2020.[2]

Chemistry

Molecule.svg

This chemistry section is incomplete.

You can help by adding to it.

MXiPr, or (IUPAC) 2-(3-Methoxyphenyl)-2-[(propan-2-yl)amino]cyclohexan-1-one, is classed as an arylcyclohexylamine drug. Specifically, an Arylcycloalkylamine[3].

Pharmacology

Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Very little is known about the pharmacology about this substance, however as an arylcyclohexamine it is reasonable to assume that it is an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole.”

Given its structural similarity to MXE and according to anecdotal reports, this substance may be a strong serotonin reuptake inhibitor (SRI).

Subjective effects

Metacogghjgjvghnition.png
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Early anecdotal reports suggest that MXiPr exhibits two plateaus: The first plateau occurs at doses around 5-20 mg and produces a two hour long experience resembling nitrous oxide, the second plateau occurs at doses around 20-40+ mg giving an experience similar to a hole, with a remarkably warmer or "dreamier" afterglow. It is not known if higher plateaus exist, and some researchers urge caution if experimenting with higher doses (as MXiPr has no known history of human use prior to late 2020).There are reports of body load occurring for up to 2 days after a small dose and seizures at very high dosages.

MXiPr can be said to share similar properties to that of MXE or O-PCE but there have been some anecdotal reports that suggest that this may have a potentially higher risk of inducing Rhabdomyolysis (Wikipedia), seizures, and amnesia. It is possible that these effects may be avoided by practicing harm reduction via keeping dosages low, usage infrequent, and avoiding combinations.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Auditory effects
Volume-up.svg

Disconnective effects
Chain-broken.svg

Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.

Additional experience reports can be found here:

Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational MXiPr use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXiPr has very little history of human usage.

If one suspects that it may be impure and are still keen on taking this substance, at the very least ensure that it to goes through first-pass metabolism by taking it orally.

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

As with other NMDA receptor antagonists, the chronic use of MXiPr can be considered moderately addictive with a high potential for abuse and is capable of producing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if one suddenly stops their usage.

Tolerance to many of the effects of MXiPr develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects.

After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).

MXiPr exhibits cross-tolerance with all dissociatives, meaning that after the consumption of MXiPr all dissociatives will have a reduced effect.

Urinary tract effects

Regarding its long-term health effects when used repeatedly and over excessive periods, MXiPr is suspected to exhibit similar bladder and urinary tract problems found with ketamine, but to a lesser extent. This is because MXiPr is far more potent than ketamine, so significantly less of substance needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:

  • Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
  • Urinary urgency - This can be described as a sudden, compelling need to urinate.
  • Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
  • Pelvic and bladder pain - Pain can develop suddenly and severely, especially since the bladder fills with urine.
  • Hematuria - Hematuria is visible blood in the urine.
  • Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using MXiPr on a daily or even weekly basis and consciously limiting one's usage of the substance.

Dangerous interactions

Ambulance2.png

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous or even life-threatening when combined with certain other substances. The following lists some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
  • Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Germany: MXiPr is controlled under the NpSG (New Psychoactive Substances Act)[4] as of July 18, 2019.[5] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[6]
  • Hungary: MXiPr was made illegal to possess, produce and sell in Hungary in April 2021.[7]

See also

External links

Discussion

References

  1. MXiPr - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=MXiPr
  2. MXiPr - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=MXiPr
  3. Isomer Design | https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=14059
  4. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  5. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020. 
  6. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  7. Amendment of Minister for Human Capacities Decree No 55/2014 of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances, 2021/225/HU